Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 12, 2004, Pages 4864-4868

  Johnston, Elizabeth ^a   Winters, Mark A ^a   Rhee, Soo Yon ^a   Merigan, Thomas C ^a   Schiffer, Celia A ^b   Shafer, Robert W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME SUBSTRATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MULTIDRUG RESISTANCE; MUTATION; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; MUTATION; OLIGOPEPTIDES; PROTEIN CONFORMATION;

EID: 9644281075     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.12.4864-4868.2004     Document Type: Article

References (16)

1. Brown, A. J., H. M. Precious, J. Whitcomb, V. Simon, E. S. Daar, R. D'Aquila, P. Keiser, E. Connick, N. Hellmann, C. Petropoulos, M. Markowitz, D. Richman, and S. J. Little. 2001. Reduced susceptibility of HIV-1 to protease inhibitors from patients with primary HIV infection by three distinct routes, abstr. 424. 8th Conf. Retrovir. Opportunistic Infect., Chicago, Ill.
2. Chen, L., A. Perlina, and C. J. Lee. 2004. Positive selection detection in 40,000 human immunodeficiency virus (HIV) type 1 sequences automatically identifies drug resistance and positive fitness mutations in HIV protease and reverse transcriptase. J. Virol. 78:3722-3732.
3. Côté, H. C., Z. L. Brumme, and P. R. Harrigan. 2001. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J. Virol. 75:589-594.
4. Ferrin, T. E., C. C. Huang, L. D. Jarvis, and R. Langridge. 1988. The MIDAS display system. J. Mol. Graphics 6:13-27.
5. Imamichi, T., S. C. Berg, H. Imamichi, J. C. Lopez, J. A. Metcalf, J. Falloon, and H. C. Lane. 2000. Relative replication fitness of a high-level 3′-azido-3′-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr→Gly) at codon 69. J. Virol. 74:10958-10964.
6. Kaldor, S. W., V. J. Kalish, J. F. Davies, B. V. Shetty, J. E. Fritz, K. Appelt, J. A. Burgess, K. M. Campanale, N. Y. Chirgadze, D. K. Clawson, B. A. Dressman, S. D. Hatch, D. A. Khalil, M. B. Kosa, P. P. Lubbehusen, M. A. Muesing, A. K. Patick, S. H. Reich, K. S. Su, and J. H. Tatlock. 1997. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 40:3979-3985.
7. King, R. W., D. L. Winslow, S. Garber, H. T. Scarnati, L. Bachelor, S. Stack, and M. J. Otto. 1995. Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease which retains susceptibility to protease inhibitors. Antivir. Res. 28:13-24.
8. Op de Coul, E., A. van der Schoot, J. Goudsmit, R. van den Burg, W. Janssens, L. Heyndrickx, G. van der Groen, and M. Cornelissen. 2000. Independent introduction of transmissible F/D recombinant HIV-1 from Africa into Belgium and The Netherlands. Virology 270:267-277.
9. Parkin, N. T., N. S. Hellmann, J. M. Whitcomb, L. Kiss, C. Chappey, and C. J. Petropoulos. 2004. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:437-443.
10. Prabu-Jeyabalan, M., E. Nalivaika, and C. A. Schiffer. 2002. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 10:369-381.
11. Rhee, S. Y., M. J. Gonzales, R. Kantor, B. J. Betts, J. Ravela, and R. W. Shafer. 2003. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 31:298-303.
12. Robinson, L. H., R. E. Myers, B. W. Snowden, M. Tisdale, and E. D. Blair. 2000. HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays. AIDS Res. Hum. Retrovir. 16:1149-1156.
13. Wang, W., and P. A. Kollman. 2001. Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance. Proc. Natl. Acad. Sci. USA 98:14937-14942.
14. Wu, T. D., C. A. Schiffer, M. J. Gonzales, J. Taylor, R. Kantor, S. Chou, D. Israelski, A. R. Zolopa, W. J. Fessel, and R. W. Shafer. 2003. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J. Virol. 77:4836-4847.
15. Yang, R., X. Xia, S. Kusagawa, C. Zhang, K. Ben, and Y. Takebe. 2002. On-going generation of multiple forms of HIV-1 intersubtype recombinants in the Yunnan Province of China. AIDS 16:1401-1407.
16. Zazzi, M., L. Romano, F. Razzolino, I. Vicenti, C. Macchiesi, S. Machetti, A. Marconi, and P. E. Valensin. 2004. Prevalence and time trends of primary and secondary antiretroviral drug resistance in a large sequence database maintained at the University of Siena, Italy, abstr. 4.23. 2nd Eur. HIV Drug Resist. Workshop, Rome, Italy.